Immatics
Celgene strikes $1.5bn cell therapy deal with Immatics
Phil Taylor
Celgene, cell therapy, Immatics, immuno-oncology, Oncology
0 Comment
X
Celgene strikes $1.5bn cell therapy deal with Immatics
https://pharmaphorum.com/news/celgene-strikes-1-5bn-cell-therapy-deal-with-immatics/
Articles/ R&D/ UK & Europe/ Views and analysis
European biotech round-up: Ablynx’s big break and more
Andrew McConaghie
European biotech, Immatics, Summit Therapeutics, UK biotech
0 Comment
European biotech: a mixture of encouraging clinical trials and new funding lift the sector.
X
European biotech round-up: Ablynx’s big break and more
https://pharmaphorum.com/views-and-analysis/european-biotech-round-ablynxs-big-break/
Amgen, Immatics strike $1bn cancer R&D deal
Richard Staines
Amgen, cancer, cancer immunotherapy, Immatics, Oncology, R&D
0 Comment
Companies to develop bispecific antibodies.
X
Amgen, Immatics strike $1bn cancer R&D deal
https://pharmaphorum.com/news/amgen-immatics-strike-1bn-cancer-rd-deal/